A list of changes in the level of risk of products reviewed in e-lactancia during the last 3 months is shown. Tap the name of a product to access to its full information.

Rituximab

Level of risk reviewed on 19/11/2019

Decreased level of risk

New scientific evidences have driven the Apilam staff to update the level of risk associated to this product.
Former level of risk, which was Low Risk, is now set to Very Low Risk.